Dedicated view
After Conservative / Palliative Care
This view includes only public records whose official title or study scope explicitly states advanced, metastatic, recurrent, refractory, later-line, supportive care, or palliative. TrialBeacon makes no screening judgment, matching, or recommendation — it simply gathers the literally relevant official entries together and provides direct links to the originals. Whether a record is still open, or relevant to any individual situation, should be determined from the official original and your physician’s judgment.
Showing the verified snapshot of official records indexed on 2026-08-16. Every link opens the live original page.
Includes only public records whose official title explicitly mentions advanced / recurrent / later-line / supportive care. No recommendations, no matching — only links to the originals. Defer to the official page and your physician’s judgment.
Please read this first. A record appearing here does not mean it is open, available or appropriate for any individual. Inclusion is based only on wording in the official record — never on any judgement by this site. Discuss anything you find with your treating doctor.
Trial records retrieved live from the ClinicalTrials.gov public API.
Select the public official records you want to take to your appointment, then generate a list. Nothing is ranked or recommended — the list only reproduces titles and links.
Not signed in — up to 5 records per list. Sign in for higher free limits, or see Pro for more exports.
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
HTL0039732 in Participants With Advanced Solid Tumours
Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
A Study of PHN-012 in Patients With Advanced Solid Tumors
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy
Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Evaluation of XYA02 in Patients With Advanced Solid Tumors
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
A Phase 1 Trial Of Safety And Initial Efficacy Of Vagal Nerve Blockade For Cancer-Induced Cachexia In Patients With Metastatic Pancreatic Adenocarcinoma
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC
A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
TT-702 in Patients With Advanced Solid Tumours.
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
ChiCTR — Chinese Clinical Trial Registry, public search
CTIS public register — search clinical trials authorised in the EU/EEA
ESMO Clinical Practice Guidelines — supportive and palliative care section
FDA — expanded access (compassionate use) information for patients
NCCN Guidelines — palliative care category listing
NCCN Guidelines for Patients — plain-language versions
药物临床试验登记与信息公示平台 — national registry of drug trials conducted in China
Whether a record is still open, current, or appropriate for any individual can only be confirmed by the official source and your treating doctor.
Ways to open the conversation with your doctor (reference only, not advice)
A template only — it teaches how to ask, and gives no answers. Adapt these to your own situation.
- Are these public records still searchable or open to enrolment?
- From the literal wording of the public titles, is there any point relevant to the current situation?
- If there is something relevant, what should I ask you about next?
- For symptoms, pain or supportive care, is there a public guideline worth prioritising as a reference?
These are only examples to help you start a conversation. They are not medical advice. All decisions should be made together with your treating doctor.